These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7080865)

  • 21. Leukaemia on myeloma.
    Webb JA; Bateman CJ; Davies JD
    Br Med J; 1971 Oct; 4(5781):231. PubMed ID: 5286613
    [No Abstract]   [Full Text] [Related]  

  • 22. A case of multiple myeloma terminating with acute myelomonocytic leukemia after long-term melphalan therapy.
    Ota H; Ikeda Y; Shibata T; Hirabayashi N
    Nihon Ketsueki Gakkai Zasshi; 1974 Feb; 37(1):49-57. PubMed ID: 4526861
    [No Abstract]   [Full Text] [Related]  

  • 23. Chronic myelomonocytic leukemia following prolonged alkylating agent therapy for multiple myeloma.
    Natazuka T; Yamaguchi T; Murayama T; Fukase M; Matsui T; Isobe T; Chihara K
    Int J Hematol; 1994 Dec; 60(4):263-5. PubMed ID: 7894029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple myeloma terminating in acute leukemia: report of two cases and review of the literature.
    Martínez-Poventud G; Fernández AC; Vélez-García E
    Bol Asoc Med P R; 1985 Oct; 77(10):419-21. PubMed ID: 3865657
    [No Abstract]   [Full Text] [Related]  

  • 25. Epistaxis and severe weakness in a patient with multiple myeloma. Therapy-related acute myeloid leukemia, pure erythroid leukemia.
    Guo C; Inghirami G; Ibrahim S; Sen F
    Arch Pathol Lab Med; 2006 Jul; 130(7):1075-6. PubMed ID: 16831041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone marrow damage due to melphalan and other cytostatic agents.
    Bezwoda WR; Hofman K; Bothwell TH; Derman DP; MacPhail AP; Mendelow B
    S Afr Med J; 1980 Sep; 58(12):479-84. PubMed ID: 6932739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of multiple myeloma with melphalan: 35 personal cases].
    Dryll A; Ryckewaert A; Kahn MF; Hayat M; de Seze S
    Sem Hop; 1970 Jan; 46(5):289-98. PubMed ID: 4327260
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacology of intravenous melphalan in patients with multiple myeloma.
    Brox L; Birkett L; Belch A
    Cancer Treat Rev; 1979 Jun; 6 Suppl():27-32. PubMed ID: 498169
    [No Abstract]   [Full Text] [Related]  

  • 30. [Multiple myeloma following chronic neutrophilia terminated with acute monocytic leukemia (AML, M 5 b)].
    Abe K; Imamura N; Mtasiwa DM; Inada T; Fujimura K; Kuramoto A
    Rinsho Ketsueki; 1989 Jun; 30(6):910-4. PubMed ID: 2795904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute myelomonoblastic leukemia in a patient with multiple myeloma.
    Colović M; Jovanović V; Ristić M
    Acta Med Iugosl; 1989; 43(1):77-82. PubMed ID: 2711863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Myeloma and myelomonocytic leukemia. Role of melphalan. Ultrastructural and cytoenzymologic study].
    Marsan C; Henon P; Quillard A; Grimaldi A; Cywiner-Golenzer C; Adotti F; Dryll A; Roujeau J
    Pathol Eur; 1973; 8(4):287-98. PubMed ID: 4523953
    [No Abstract]   [Full Text] [Related]  

  • 33. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
    Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D
    J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple myeloma and acute myelomonocytic leukemia.
    Kyle RA; Pierre RV; Bayrd ED
    N Engl J Med; 1970 Nov; 283(21):1121-5. PubMed ID: 5273282
    [No Abstract]   [Full Text] [Related]  

  • 35. [Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)].
    Robak T; Krykowski E; Płuzańska A; Olszańska-Skorek T; Urbańska-Ryś H; Polkowska-Kulesza E; Błasińska-Morawiec M; Mazurowa A
    Pol Tyg Lek; 1983 Apr; 38(16):481-4. PubMed ID: 6579509
    [No Abstract]   [Full Text] [Related]  

  • 36. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
    San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
    J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy related acute non-lymphocytic leukemia: report of 4 cases.
    Atichartakarn V; Punyammalee B; Nitiyanant P
    Southeast Asian J Trop Med Public Health; 1985 Sep; 16(3):421-30. PubMed ID: 4095607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-dose intravenous melphalan in advanced multiple myeloma.
    Bäck H; Lindblad R; Rödjer S; Westin J
    Acta Haematol; 1990; 83(4):183-6. PubMed ID: 2115714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiation and drug therapies, and leukemia.
    Potolsky A; Creger WP
    Annu Rev Med; 1973; 24():75-82. PubMed ID: 4514215
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.